SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$2.91 -0.53%

-$0.02 today

Market cap
$262.16M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 1.75M

Average 0.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$44.78M

FY 2025 · Annual

Investing Cash Flow

-$121.71M

FY 2025 · Annual

Financing Cash Flow

$168.30M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.14M)(18.74M)(42.19M)(34.11M)13.27M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
Deferred Income Tax00000
Stock-Based Compensation2.31M2.67M2.42M2.94M5.21M
Change in Working Capital11.68M(237.58K)2.33M(2.3M)(3.69M)
Accounts Receivables12.56M2.45M5.56M(54.96K)(891.83K)
Inventory00000
Accounts Payables(2.94M)(779.43K)(2.7M)923.32K1.48M
Other Working Capital2.06M(1.91M)(528.64K)(3.17M)(4.28M)
Other Non-Cash Items3.48M(10.45M)8.58M(5.62M)(62.66M)
Operating Cash Flow1.99M(23.46M)(25.12M)(34.29M)(44.78M)
Capital Expenditures(10.94M)(2.17M)(197.15K)(337.26K)(933.15K)
Acquisitions (Net)0000500
Purchases of Investments000(37.45M)(142.04M)
Sales of Investments00025.82M21.26M
Other Investing Activities076.39K44.45K00
Investing Cash Flow(10.94M)(2.09M)(152.7K)(11.96M)(121.71M)
Debt Repayment1.54M(1.19M)(390.45K)(907K)(418.41K)
Common Stock Issued6.75K7.68M020.41K168.73M
Common Stock Repurchased0(5.52M)000
Dividends Paid00000
Other Financing Activities34.34M76.97K59.66M(286.04K)(11.96K)
Financing Cash Flow35.89M1.05M66.77M(1.17M)168.3M
Effect of Forex Changes0018.14K(241.2K)(213.5K)
Net Change in Cash26.93M(24.5M)41.52M(47.67M)1.6M
Free Cash Flow(8.96M)(25.63M)(25.32M)(34.63M)(45.71M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$13.3M
+ D&A$3.1M
+ Stock-Based Comp$5.2M
+ Deferred Tax$0
- Working Capital-$3.7M
- Other Non-Cash-$62.7M
= Operating Cash Flow-$44.8M
- Capex-$933.2K
= Free Cash Flow-$45.7M

Analysis

FY2025 free cash flow is -$45.7M. FCF conversion is -344.4% of net income. Operating cash flow was -$44.8M, with capex of -$933.2K. The largest bridge item is Other Non-Cash at -$62.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
25-NSE25-NSE filingOct 22, 2026
8-KCurrent reportOct 13, 2026
4Statement of changes in beneficial ownershipSep 18, 2026
424B3424B3 filingAug 21, 2026

Does SABS generate free cash flow?

SAB Biotherapeutics, Inc. (SABS) generated -$45.71M of free cash flow in fiscal 2025.

How much operating cash flow does SABS produce?

Operating cash flow was -$44.78M, before capital expenditures of $933,151.00.